首页> 外文期刊>Medical principles and practice: international journal of the Kuwait University, Health Science Centre >Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease.
【24h】

Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease.

机译:用Graves病患者的甲状腺过氧化物酶抗体测定抗甲状腺刺激激素受体抗体的水平。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To determine the levels of anti-thyroid-stimulating hormone receptor antibody (TRAb) and thyroid peroxidase antibodies (TPO) in Omani patients with Graves' disease (GD). SUBJECTS AND METHODS: ELISA was used to measure the levels of TRAb and TPO in sera of 111 patients with GD, 40 patients with systemic lupus erythematosus (SLE) and 50 healthy normal subjects. Seventy-eight GD patients received iodine-131 treatment while 33 newly diagnosed patients did not receive any treatment. RESULTS: The levels of TRAb in the patients with GD, SLE and normal subjects were 7.24 9+/-0.623, 1.04+/-0.179 and 0.539+/-0.070 units/liter, respectively. Elevated levels of TRAb were found in 75, 5 and 2% of patients with GD, SLE and normal subjects, respectively. For anti-TPO antibodies, the levels were 713.331+/-97.905, 85.575+/-34.936 and 22.96+/-4.544 lU/ml, for patients with GD, SLE and normal subjects, respectively. The elevated level of anti-TPO antibodies were found in 72, 15 and 6% of patients with GD, SLE and normal subjects. Statistically significant differences in positive levels of TRAb and anti-TPO antibodies were found in patients with GD as compared to SLE and normal subjects (p<0.001). The treated GD patients had lower levels of TRAb than untreated, but no difference was detected in the levels of anti-TPO antibodies between the treated and not treated. CONCLUSION: High levels of TRAb and TPO were detected in Omani patients with GD. TRAb may be helpful in the diagnosis and monitoring the efficacy of iodine-131 treatment in GD patients.
机译:目的:确定阿曼Graves病(GD)患者的抗甲状腺刺激激素受体抗体(TRAb)和甲状腺过氧化物酶抗体(TPO)水平。研究对象和方法:采用ELISA法检测111例GD患者,40例系统性红斑狼疮(SLE)患者和50例健康正常人血清中的TRAb和TPO水平。 78名GD患者接受了碘131治疗,而33名新诊断患者未接受任何治疗。结果:GD,SLE和正常人的TRAb水平分别为7.24 9 +/- 0.623、1.04 +/- 0.179和0.539 +/- 0.070单位/升。在GD,SLE和正常受试者中,分别有75%,5%和2%的患者发现TRAb水平升高。对于GD,SLE和正常受试者,抗TPO抗体的水平分别为713.331 +/- 97.905、85.575 +/- 34.936和22.96 +/- 4.544 lU / ml。在GD,SLE和正常受试者的患者中,发现72、15和6%的抗TPO抗体水平升高。与SLE和正常受试者相比,GD患者的TRAb和抗TPO抗体阳性水平存在统计学上的显着差异(p <0.001)。治疗的GD患者的TRAb水平低于未治疗的患者,但未治疗和未治疗的抗TPO抗体水平均未发现差异。结论:阿曼GD患者检测到高水平的TRAb和TPO。 TRAb可能有助于诊断和监测GD患者中碘131治疗的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号